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Background: Somatic symptom overlap between depression and insomnia has emerged as a 
major concern. Self-report measures such as the Beck Depression Inventory Second Edition 
(BDI-II) include somatic symptoms related to depression that are also present in the research 
diagnostic criteria for insomnia. This study aimed firstly to examine the relationship between 
the cognitive and somatic factors of the BDI-II and global scores on the Pittsburgh Sleep Quality 
Index (PSQI) in individuals presenting for insomnia treatment and secondly to examine whether 
treating insomnia in depressed individuals with insomnia will lead to a reduction in their depres-
sive symptoms and whether this reduction is related to a decrease in the somatic or cognitive 
factors of depressive symptoms.
Methods: A total of 379 individuals (133 males and 246 females), with a mean (M) age of 
49.95 (standard deviation [SD] = 14.15) years, were used to address the first aim. To address 
the second aim, a total of 64 participants (27 males and 37 females) with both insomnia and 
depressive symptoms were treated for their insomnia. Their ages ranged between 22 and 
87 (M = 50.97, SD = 15.13) years.
Results: A significant relationship was found between both the cognitive and somatic factors 
of the BDI-II and global scores on the PSQI. Furthermore, although results in this study are 
only suggestive, they lend support to the idea that the relationship between insomnia and depres-
sion is not due to somatic symptom overlap. Results may also support the hypothesis that 
insomnia is primary to the presentation of depressive symptoms.
Conclusion: Clinicians and health care providers could initially treat insomnia in individuals 
suffering from insomnia who also experience depressive symptoms, as this will not only remit 
insomnia but also abate the accompanying depressive symptoms.
Keywords: cognitive depressive symptoms, somatic depressive symptoms, symptom 
overlap
Introduction
Insomnia is the most common sleep problem, and its consequences are serious.1–5 
Severe insomnia is associated with increased psychiatric illness, with depression being 
the most common.6 Investigating the relationship between depression and insomnia 
is important due to their frequent co-occurrence.6–8 A better understanding of the 
relationship between the two conditions could aid clinicians in making informed deci-
sions about the best treatment approaches for comorbid insomnia and depression.9
The disorders share a complex theoretical and clinical relationship.7 It is estimated 
that 60% of adults meeting criteria for major depressive disorders (MDDs) complain 
of insomnia, and approximately 10%–20% of individuals diagnosed with insomnia 
meet criteria for MDDs.10 The direction of the relationship between insomnia 





and depression has emerged as a major concern in the 
literature.11–14 Although some suggest that depression is the 
largest and most consistent risk factor for chronic insomnia,13,14 
others argue that insomnia is a risk factor for the development 
of depression.12 The Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition, Text Revision (DSM-
IV-TR) classifies insomnia into two categories: primary 
insomnia, associated with sleep onset and/or maintenance 
problems, and secondary insomnia, associated with medical 
or mental health conditions.15 This classification implies that 
insomnia experienced in combination with psychological 
disorders such as depression is secondary to (caused by) the 
psychological disorder.
Interestingly, much research suggests otherwise. Following 
an extensive review of the literature, Harvey concluded that 
insomnia precedes the development of depression.16 More 
recent findings are in line with Harvey’s conclusion. In a 
sample of 1014 youths, Johnson et al found that after adjust-
ing for gender, race, and prior anxiety disorders, insomnia 
occurred first in 69% of cases with comorbid insomnia and 
depression.12 On the other hand, depression was not found 
to be associated with the onset of insomnia. Similarly, in a 
longitudinal study in Switzerland, Buysse et al found that 
pure and comorbid insomnia was associated with future 
episodes of major depression or pure insomnia.17 However, 
pure depression was less strongly related to future episodes 
of comorbid insomnia and depression, pure depression, or 
pure insomnia.17
A better understanding of the causal nature of the rela-
tionship between insomnia and depression may be obtained 
by treating one condition and monitoring changes in the other. 
Research in this area has been limited. Morawetz found that 
70% of individuals with insomnia and depression who 
received treatment for their insomnia experienced a decrease 
in their depression. Individuals who did not experience 
improvement in their insomnia did not show improvement in 
their depression. Morawetz concluded that these results were 
suggestive of depression being secondary to insomnia.18 
Although different methods were utilized to treat insomnia, 
other researchers have come to a similar conclusion.19,20
Research treating depression and observing insomnia has 
been very limited. Carney et al reported improvements in 
insomnia following the treatment of depression.21
A second major concern is associated with the overlap 
of some somatic symptoms present in both conditions 
 (concentration difficulties, reduced sleep, and fatigue).21 
More specifically, self-report measures assessing the sever-
ity of depression, such as the Beck Depression Inventory 
Second Edition (BDI-II),23 include somatic symptoms related 
to depression that are also present in the research diagnostic 
criteria for insomnia, eg, insomnia, irritability, fatigue, con-
centration difficulties, motivation, and mood disturbance.24 
This overlap makes it difficult to distinguish whether the 
elevated total scores reported on measures of depression such 
as the BDI-II in those with sleep problems reflect genuine 
depression, or whether the elevated scores are due to the 
overlap of the somatic symptoms common to both conditions. 
There is very little research addressing this issue.
One study addressed this issue by examining the correla-
tion of each item on the BDI-II with measures of sleep. 
Utilizing the Duke Structured Interview for Sleep Disorders 
(DSISD),25 participants were screened for the presence of 
insomnia; they were also evaluated for the presence of MDDs 
using the structured clinical interview for the DSM-IV-TR.26 
Carney et al allocated participants into two groups (insomnia 
with or without MDD). Following administration of the 
BDI-II, they found that the group with comorbid insomnia 
and depression scored significantly higher than the individuals 
with pure insomnia on 13 of the 21 items of the BDI-II. These 
items were sadness, crying, past failure, self-dislike, pessimism, 
anhedonia, guilt, agitation, indecision, worthlessness, energy, 
hypersomnia, and loss of appetite.26 However, the two groups 
did not differ on eight items (insomnia, irritability, suicidal 
thoughts, decreased concentration, fatigue, libido, thoughts 
of punishment, and critical thoughts of the self), indicating 
some degree of symptom overlap.
Studies reported in this paper have examined improve-
ments in the level of depression following the treatment of 
insomnia without considering potential differential response 
in the cognitive and somatic aspects of depression.18–20 In fact, 
no study has examined whether improvement in individuals’ 
mood states were due to the reduced scores on the somatic 
or cognitive aspects of their depressive symptoms.
The present study aimed to examine the relationship 
between both the cognitive and somatic factors of the BDI-II 
and insomnia. This study also aimed to explore whether an 
initial treatment of insomnia in individuals presenting with both 
insomnia and depressive symptoms who volunteered to take 
part in an intervention for insomnia would result in a reduction 
in depressive symptoms and whether this decrease would be 
due to a reduction in the somatic or cognitive factors or both.
Method
Participants
A total of 379 individuals (133 males and 246 females) who 
were concerned about their sleep and volunteered to take 
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part in an intervention for insomnia participated in this study. 
Their ages ranged between 18 and 90 (mean [M] = 49.95, 
standard deviation [SD] = 14.15) years.
Of the 379 participants, a subsample of individuals who 
met the Lichstein et al27 criteria for insomnia, who scored 
greater than 12 on the BDI-II prior to intervention and who 
also completed the intervention and provided postinterven-
tion data on the Pittsburgh Sleep Quality Index (PSQI) and 
the BDI-II, were selected. A total of 64 participants (27 males 
and 37 females) were identified. Their ages ranged between 
22 and 87 (M = 50.97, SD = 15.13) years.
Measures
The Pittsburgh sleep Quality Index 
(PsQI)28
The PSQI is a self-rated questionnaire assessing the indi-
vidual’s perception of the quality of his/her sleep over the 
preceding month. The PSQI consists of 19 questions that are 
grouped into seven components reflecting different aspects 
of sleep. Each question is scored on a scale ranging from 
0 to 3, with 0 indicating the absence of sleep complaints and 
3 indicating the most severe complaints. The seven compo-
nents are then added to form the global score of the PSQI, 
ranging from 0 to 21, with higher scores indicating worse 
sleep quality.28 Scores higher than 5 on the global score are a 
reflection of severe sleep problems.29 The PSQI is a reliable 
measure, with test–retest correlation of 0.87 for the global 
scores and between 0.53 and 0.88 for the component scores 
for patients with primary insomnia.30 Good evidence of 
validity has been reported.31,32
The Beck Depression Inventory  
second edition (BDI-II)23
The BDI-II measures the severity of depressive symptoms 
in accordance with the DSM-IV. The BDI-II is a 21-item 
self-report measure, with each item rated on a 4-point ordinal 
response scale ranging from 0, which indicates the absence 
of symptoms, to 3, indicating the most severe symptoms. 
The total BDI-II score is the sum of the 21 items and ranges 
from 0 to 63, with higher scores indicating more severe 
depressive symptoms. Scores ranging between 0 and 13 
reflect an absence of, or minimal, depressive symptoms; scores 
between 14 and 19 reflect mild depressive symptoms; between 
20 and 28 reflect moderate depressive symptoms; and 
between 29 and 63 reflect severe depressive symptoms.23 
Beck et al suggest that the instrument measures two factors: 
the somatic–affective factor/subscale, which includes 12 of 
the 21 items (loss of pleasure, crying, agitation, loss of 
interest, indecisiveness, loss of energy, changes in sleeping 
patterns, irritability, changes in appetite, concentration dif-
ficulties, tiredness or fatigue, and loss of interest in sex), 
and the cognitive factor/subscale, which includes nine items 
(sadness, pessimism, past failure, guilt, punishment feel-
ings, self-dislike, self-criticalness, suicidal thoughts, and 
worthlessness).23 The BDI-II has an internal consistency 
coefficient α of 0.93 and a test–retest reliability of 0.93.23 
Moreover, the BDI-II has been found to be a valid scale for 
measuring depression in chronic pain patients33 and traumatic 
brain injury,34 and, more importantly, the BDI-II has high 
accuracy in discriminating between individuals diagnosed 
with insomnia and depression and those diagnosed with 
insomnia without depression.26
Although a formal clinical interview for depression 
might have been preferred, it was not feasible, as the primary 
focus of the main study was concerned with insomnia. Readers 
should note that this paper reports on depressive symptoms 
and not clinically diagnosed depression.
Procedure
Following the approval of La Trobe University, Melbourne, 
Australia, participants were recruited through advertisements 
in newspapers, notices in community health centers, and 
through word of mouth.
A package of questionnaires, including the PSQI and 
the BDI-II, was sent to all prospective participants. To be 
eligible to participate in the study, individuals needed to meet 
the criteria for insomnia specified by Lichstein et al,27 ie, they 
had to have a self-reported sleep onset latency of at least 
30 minutes or be awake for at least 30 minutes after sleep 
onset at least 3 nights per week and had experienced sleep 
difficulties for at least 6 months. Furthermore, due to ethical 
concerns, participants were included in the study only if they 
scored below 29 on the BDI-II. Informed consent was 
obtained from all selected participants. Participants were 
assured of the confidentiality of the information and the right 
to withdraw from the study at any stage.
The intervention involved three treatment groups: 
a therapist-led group, a group who received a self-help manual, 
and a group who received a self-help manual and weekly 
telephone calls from a therapist. The content that all partici-
pants were exposed to was as similar as possible and based 
on the treatment manual published by Morin and Espie.4 
Those in the self-help groups received a manual that was based 
on the one published by Morin and Espie in 2003. The treat-
ment manual comprised six modules. Each module provided 
information and strategies for participants to implement to 





improve their sleep. The first module predominantly focused 
on environmental factors (eg, noise, temperature) that affect 
people’s sleep. Module 2 examined how poor sleep hygiene 
(a set of behaviors that are known to influence sleep, eg, 
vigorous exercise too close to bedtime or nicotine or caffeine) 
can impact on sleep quality and quantity. The third module 
focused on six behavioral strategies for good sleep, collec-
tively known as stimulus control. Module 4 described relax-
ation exercises for participants to incorporate into their 
prebedtime routine. The fifth module addressed cognitive 
factors that might be contributing to a long sleep onset or 
preventing people from resuming sleep if they wake during 
the night. The strategies described include, but are not limited 
to, prioritizing activities, problem solving, and assertiveness. 
The final module utilized the principles of relapse prevention 
and encouraged participants to review their progress in rela-
tion to the goals they originally set for themselves. Those in 
the therapist-led group were exposed to this content by an 
experienced therapist in weekly 60-minute sessions con-
ducted over a 6-week period. Those in the self-help groups 
were asked to complete one module each week over the same 
period of time. For the purposes of this study, data from the 
three groups were combined, as the differences in the out-
come between the three groups were not significant. Thus, 
all participants received an intervention using the commonly 
accepted cognitive behavioral treatment approach for 
insomnia.
Results
Prior to intervention, a significant positive correlation was 
found between global scores on the PSQI (M = 13.36, 
SD = 3.27) and total scores on the BDI-II (M = 14.55, 
SD = 10.37), r (N = 379) = 0.41, P , 0.001, R2 = 0.17, 95% 
confidence interval (0.32, 0.49). To further investigate 
whether this relationship differed between the somatic and 
cognitive factors of the BDI-II, a significant positive relation-
ship was found between global scores on the PSQI and the 
cognitive factor of the BDI-II (M = 9.92, SD = 6.28), 
r (N = 379) = 0.41, P , 0.001, R2 = 0.17 (0.32, 0.49) and 
also with the somatic factor of the BDI-II (M = 4.61, 
SD = 4.90), r (N = 379) = 0.34, P , 0.001, R2 = 0.12 (0.25, 0.43). 
Although a formal test of the difference between the two 
correlation coefficients using Steiger’s Z 35 failed to reach 
significance (Z = 1.12, P = .26), the relationship for the 
somatic factor was relatively weaker in comparison with that 
observed between the PSQI and the cognitive factor. If the 
relationship between insomnia and depression was due to 
overlap of somatic items on both instruments, one would 
have expected the correlation with the somatic factor of 
the BDI-II and the PSQI to be superior to that with the cogni-
tive factor. All three correlations reported were of moderate 
magnitude.36 Figure 1 shows a matrix of scatterplots among 
the variables prior to intervention.
To investigate how the intervention impacted on the 
cognitive and somatic factors of depression, paired-sample 
t-tests were used. The mean score for the somatic factor after 
intervention (M = 4.24, SD = 3.42) was significantly lower 
than the mean score before intervention (M = 6.15, 
SD = 3.08), t (65) = 5.48, P , 0.001, d = 0.67 (0.40, 0.94). 
For the cognitive factor, the mean score after intervention 
(M = 8.09, SD = 4.82) was also significantly lower than the 
mean score before intervention (M = 12.41, SD = 3.54), 
t (65) = 7.23, P , 0.001, d = 0.89 (0.60, 1.17). Although 
both effect sizes were in the moderate range,36 Steiger’s Z 35 
revealed that these effect sizes were significantly different 
(Z = 2.81, P = 0.004), with a larger effect observed on the 
cognitive factor. The mean of the BDI-II total scores after 
intervention (M = 12.51, SD = 7.59) was significantly lower 
than the mean scores of the BDI-II before intervention 
(M = 18.63, SD = 4.54, t (64) = 7.59, P , 0.001, d = 0.94 
(0.65, 1.23). The effect size was moderate.36 Figure 2 shows 
the means for the PSQI global scores, the BDI-II total scores, 
and the somatic and cognitive factors prior to and following 
























Figure 1 Matrix scatterplot showing Pittsburgh sleep Quality Index (PsQI) global 
scores prior to intervention (global), the Beck Depression Inventory second edition 
(BDI-II) prior to intervention (bdipre), the cognitive factor score on the BDI-II prior 
to intervention (bdiprecog), and the somatic factor score on the BDI-II prior to 
intervention (bdipresa).
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A paired-sample t-test showed that the mean global PSQI 
score after intervention (M = 9.28, SD = 3.37) was significantly 
lower than the mean score of the PSQI before intervention 
(M = 14.14, SD = 2.56), t (63) = 12.36, P , 0.001, d = 1.55 
(1.18, 1.91). The effect size was large.36
The mean of the BDI-II total scores after intervention 
(M = 12.51, SD = 7.59) was significantly lower than the mean 
scores of the BDI-II before intervention (M = 18.63, 
SD = 4.54, t (64) = 7.59, P , 0.001, d = 0.94 (0.65, 1.23). 
The effect size was moderate.36
A Pearson correlation revealed that the change in global 
scores on the PSQI was significantly positively correlated 
with the change of scores on the BDI-II total scores, 
r (N = 63) = 0.43, P , 0.001, R2 = 0.18 (0.20, 0.61). There 
was also a positive significant relationship between the 
change in global scores and the change in cognitive scores 
on the BDI-II, r (N = 63) = 0.44, P , 0.001, R2 = 0.19 
(0.21, 0.62). However, there was no significant relationship 
between global scores and the change in somatic scores on 
the BDI-II, r (N = 63) = 0.23, P = 0.06, R2 = 0.05 (0.01, 0.45).
Discussion
Prior to intervention, a positive relationship was found 
between insomnia, as measured by the PSQI, and depressive 
symptoms, as measured by the BDI-II, and for both the 
somatic and cognitive factors. Although there was no sig-
nificant difference between the cognitive and somatic factors 
and the relationship with the PSQI, this relationship 
accounted for 17% of the shared variance with the cognitive 
factor in comparison with only 12% of the shared variance 
with the somatic factor. Even though the findings are not 
statistically significant and are only suggestive, this finding 
is surprising and contradicts the concerns raised in the 
 literature22 that the relationship between insomnia and depres-
sive symptoms is due to the somatic symptom overlap in 
both conditions. If this were the case, one would expect the 
correlation to be much higher with the somatic factor than 
with the cognitive factor. This supports Carney et al’s findings, 
which suggest that the relationship between insomnia and 
depressive symptoms is genuine and not due to measurement 
artifact.26
















Figure 2 Means for the Beck Depression Inventory second edition (BDI-II) total scores, the cognitive factor score on the BDI-II (BDIcog), the somatic factor score on the 
BDI-II (BDIsa), and the Pittsburgh sleep Quality Index global scores (Global-Pre and Global-Post) prior to and following the treatment of insomnia.





Those receiving treatment for their insomnia also showed 
a decrease in their depressive symptoms. Following inter-
vention, PSQI global scores were significantly reduced, and 
the magnitude of this change was large. Furthermore, total 
scores on the BDI-II were also significantly reduced. However, 
the magnitude of the decrease in depressive symptoms was 
moderate. This is possibly due to the fact that participants 
with severe depressive symptoms were excluded from the 
study. A different magnitude of effect for depressive symp-
toms may have been observed had individuals with severe 
depressive symptoms been included. Future research ought 
to investigate this possibility. This result is similar to previ-
ous work that showed that exclusive treatment of insomnia 
in individuals experiencing both depression and insomnia 
resulted in decreases in depression.18–20
The pattern of change differed for the somatic and cogni-
tive factors on the BDI-II. Interestingly, the cognitive factor 
was reduced more in comparison with the somatic factor. 
This finding could be explained by the results reported earlier, 
which found a stronger correlation between cognitive scores 
and the PSQI scores. Although both factors showed a moder-
ate reduction, the difference between the two effect sizes was 
significant.
Those reporting the most improved sleep showed the 
most effective change on the total scores of the BDI-II. 
However, the relationship for change of scores between 
insomnia and depressive symptoms was found only for the 
cognitive factor accounting for 23% of the shared variance 
and not found for the somatic factor accounting for a small 
0.5% of the shared variance. These findings strengthen the 
conclusion made earlier in this study, that the relationship 
between insomnia and depressive symptoms is a genuine 
relationship and is not due to the measurement artifact of 
shared somatic items in both instruments.
An implication of this study is that individuals with both 
insomnia and depressive symptoms may benefit from an ini-
tial treatment for their insomnia, as this not only will improve 
their sleeping but also may improve their mood state. 
 Following improvements on their insomnia and possibly 
depressive symptoms, therapy may be directed to treat any 
residual depression.
This study is not without its limitations. Although a 
 clinical interview for depression might have been preferred, 
it was not feasible for this study. The small sample size of 
64 participants must not be overlooked, and future research 
should target a larger sample size to confirm the current 
findings. To select a sample of individuals with sleep prob-
lems who were also experiencing some degree of depression, 
the present study required a score of more than 12 on the 
BDI-II following the descriptive labels provided by Beck et al 
to include those with mild and moderate depression.22 However, 
Beck et al proposed a cutoff of 17 as a good criterion for 
clinical research, and this was used by Carney et al.26 The use 
of a higher cutoff was precluded in this study, as the sample 
size would have been too small to allow for powerful analyses. 
Furthermore, being the first study to explore somatic and 
cognitive symptoms and their relationship with insomnia, 
there was a need to include individuals experiencing mild 
depressive symptoms. Future research should focus more on 
this issue of the appropriate level of depressive symptoms 
to include in studies of this kind. As reported earlier, the 
PSQI has seven components that explore various aspects 
of sleep quality, and future research could examine the 
relationship between these components and somatic and 
cognitive symptoms.
In conclusion, this is the first study to explore the relation-
ship between insomnia and depressive symptoms, and specifi-
cally the somatic and cognitive factors of the BDI-II. The study 
revealed some interesting and unexpected findings. Taken 
together, the findings from the current study suggest that 
there is a genuine relationship between insomnia and depres-
sive symptoms and that this relationship is not due to the 
somatic symptom overlap seen in both conditions. Furthermore, 
following the treatment of insomnia, depressive symptoms 
were reduced. More importantly, the cognitive factor expe-
rienced the most reduction in comparison with the somatic 
factor, which experienced no reduction. The current findings 
may lend support to the hypothesis that depression is second-
ary to insomnia.
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